Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
R. Buhl, R. Abrahams, L. Bjermer, E. Derom, M. Flezar, J. Hébert, A. Veale, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, L. McGarvey (Mainz, Ingelheim, Tübingen, Germany; Morgantown, Ridgefield, United States Of America; Lund, Sweden; Ghent, Belgium; Golnik, Slovenia; Québec, Burlington, Canada; Adelaide, Australia; Alkmaar, Netherlands; Belfast, United Kingdom)
Source: International Congress 2014 – Asthma and COPD devices and treatments
Session: Asthma and COPD devices and treatments
Session type: Thematic Poster Session
Number: 922
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Buhl, R. Abrahams, L. Bjermer, E. Derom, M. Flezar, J. Hébert, A. Veale, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, L. McGarvey (Mainz, Ingelheim, Tübingen, Germany; Morgantown, Ridgefield, United States Of America; Lund, Sweden; Ghent, Belgium; Golnik, Slovenia; Québec, Burlington, Canada; Adelaide, Australia; Alkmaar, Netherlands; Belfast, United Kingdom). Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies. Eur Respir J 2014; 44: Suppl. 58, 922
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: